Medicinal cannabis shares crash lower

With the local market following the lead of US markets and sinking lower today, a good number of sectors have sunk into the red.

One area of the market which has fallen more than most is the medicinal cannabis industry.

Here is the state of play in the industry at the moment:

  • The Auscann Group Holdings Ltd (ASX: AC8) share price has fallen almost 3% to $1.61
  • The Cann Group Ltd (ASX: CAN) share price is down 4.5% to $3.12.
  • The Creso Pharma Ltd (ASX: CPH) share price is lower by 4% to 99 cents.
  • The Hydroponics Company Ltd (ASX: THC) share price is down 3.5% to 82 cents.
  • The MGC Pharmaceuticals Ltd (ASX: MXC) share price is off 4% to 11.5 cents.
  • The MMJ Phytotech Ltd (ASX: MMJ) share price has dropped 3% to 50.5 cents.

What happened?

While Cann Group’s decline could be related to its quarterly update released this morning, I think the main catalysts for these declines have been a combination of profit taking and investors going into risk-off mode following a sizeable drop in US equities.

After all, Australian medicinal cannabis shares have been some of the biggest movers on the market since the start of the year. The AusCann share price, for example, has more than doubled in value in 2018 even after a series of notable declines over the last few days.

And with so much future growth built into their shares already, they certainly are some of the most high risk shares on the market.

Should you buy the dip?

While one of two of these shares could go on to have extremely bright futures, at this stage it is a little hard to know which ones will be the winners and which will be the losers.

So for now, investors may be better off focusing on other areas of the market until it becomes clear just who is going to be the market leader in Australia.

In the meantime, I think these blue chip shares would be great options for investors in 2018 and expect them to beat the market.

Top 3 ASX Blue Chips To Buy In 2018

For many, blue chip stocks mean stability, profitability and regular dividends, often fully franked..

But knowing which blue chips to buy, and when, can be fraught with danger.

The Motley Fool’s in-house analyst team has poured over thousands of hours worth of proprietary research to bring you the names of "The Motley Fool’s Top 3 Blue Chip Stocks for 2018."

Each one pays a fully franked dividend. Each one has not only grown its profits, but has also grown its dividend. One increased it by a whopping 33%, while another trades on a grossed up (fully franked) dividend yield of almost 7%.

The names of these Top 3 ASX Blue Chips are included in this specially prepared free report. But you will have to hurry. Depending on demand – and how quickly the share prices of these companies moves – we may be forced to remove this report.

Click here to claim your free report.

Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

The 5 mining stocks we’re recommending in 2019…

For decades, Australian mining companies have minted money for individual investors like you and me. But if you believe the pundits and talking heads on TV, those days are long gone. Finito! Behind us forever…

We say nothing could be further from the truth. To earn the really massive returns, you’ve got to fish where others aren’t fishing—and the mining sector could be primed for a resurgence. That’s why top Motley Fool analysts just revealed their exciting new research on 5 ASX miners they believe could help you profit in 2019 and beyond…


The best way we see to play the global zinc shortage… Our #1 favourite large-cap miner (hint: it’s not BHP)… one early-stage gold miner we think could hit the motherlode… Plus two more surprising companies you probably haven’t heard of yet!

For free access to our brand-new research, simply click here or the link below. But be warned, this research is available free for a limited time only, and we reserve the right to withdraw it at any time.

Click here for your FREE report!